NYSE:IQV - Iqvia Stock Price, News & Analysis

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) announced its earnings results on Wednesday, July, 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.38 by $0.01. The medical research company earned $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. Iqvia's revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.29 EPS. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Iqvia.

Iqvia issued an update on its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share (EPS) guidance of $6.25-6.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.33. The company issued revenue guidance of $11.00-1.15 billion, compared to the consensus revenue estimate of $11.02 billion.

19 brokers have issued 1-year target prices for Iqvia's stock. Their forecasts range from $136.38 to $180.00. On average, they expect Iqvia's stock price to reach $163.3363 in the next twelve months. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Iqvia.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

News headlines about IQV stock have been trending negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iqvia earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Iqvia.

Iqvia saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 2,240,600 shares, a decrease of 9.5% from the July 31st total of 2,474,900 shares. Based on an average trading volume of 1,230,000 shares, the days-to-cover ratio is presently 1.8 days. Approximately 1.3% of the company's shares are short sold. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Eloxx Pharmaceuticals (ELOX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), NIC (EGOV), Zoetis (ZTS) and Workday (WDAY).

Iqvia's stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.35%), BlackRock Inc. (6.86%), BlackRock Inc. (6.86%), Janus Henderson Group PLC (1.85%), Janus Henderson Group PLC (1.85%) and AQR Capital Management LLC (1.43%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, AQR Capital Management LLC, Eminence Capital LP, Bank of New York Mellon Corp, Quest Capital Management Inc. ADV, AMF Pensionsforsakring AB and Highline Capital Management L.P.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Nuveen Asset Management LLC, Egerton Capital UK LLP, BlackRock Inc., BlackRock Inc., Putnam Investments LLC, Janus Henderson Group PLC and Janus Henderson Group PLC. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $152.94.

Iqvia has a market capitalization of $29.96 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]